Scancell Holdings Plc Hardman Report: New frontiers in T-cell activation

TIDMSCLP

Scancell Holdings Plc

26 September 2016

Hardman Research: New frontiers in T-cell activation

New frontiers in T-cell activation and targeting: Scancell is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications. ImmunoBody is a DNA vaccine which stimulates high avidity anti-tumour T-cells for use as a monotherapy or in combination with checkpoint inhibitors. Moditope targets modified antigens and stimulates powerful anti-tumour T-cell responses for use in advanced and hard-to-treat cancers. Both platforms are targeting multi-billion dollar markets. The recent capital increase will be used to advance both platforms to the next stage of development and investment in corporate infrastructure.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/scancell-documents/26.09.16-new-frontiers-in-t-cell-activation-and-targeting.pdf

 
 To contact us:      Contact: Dr Martin Hall 
  Hardman & Co        [e-mail] 
  11/12 Tokenhouse    Dr Dorothea Hill 
  Yard                [e-mail] 
  London              Dr Gregoire Pave 
  EC2R 7AS            [e-mail] 
                      Telephone: [phone] 
                      Follow us on Twitter @HardmanandCo 
 

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASEEFIDFMSEIU

(END) Dow Jones Newswires

September 26, 2016 02:15 ET (06:15 GMT)